Remission in Subjects With Crohn's Disease, 1 Year Phase

PHASE3CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

January 31, 2005

Study Completion Date

December 31, 2008

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

Double-blind (DB) adalimumab placebo

Double-blind nonactive matching subcutaneous injection

BIOLOGICAL

DB adalimumab 40 mg eow

Double-blind adalimumab 40 mg every other week by subcutaneous injection

BIOLOGICAL

DB adalimumab 40 mg ew

Double-blind adalimumab 40 mg every week by subcutaneous injection

BIOLOGICAL

OL adalimumab 40 mg

Open-label adalimumab every other week or every week by subcutaneous injection

Trial Locations (43)

10021

New York Presbyterian Hospital, New York

10029

Daniel Present, New York

11021

Long Island Clinical Research Associates, Great Neck

11042

NY Center for Clinical Research, Lake Success

14607

Rochester Institute for Digestive Diseases, Rochester

15224

Peter Molloy, MD, Pittsburgh

16635

Altoona Center for Clinical Research, Duncansville

21401

Digestive Disorders Associates, Annapolis

22902

Charlottesville Medical Research, Charlottesville

27103

Digestive Health Specialists, Winston-Salem

27599

UNC School of Medicine, Chapel Hill

28207

Charlotte Gastroenterology and Hepatology, Charlotte

28262

Carolina Research Associates, Charlotte

30342

Atlanta Gastroenterology Assoc., Atlanta

31404

Southeastern Digestive & Liver Disease, Savannah

32789

Shafran Gastroenterology Center, Winter Park

33331

Cleveland Clinic Florida, Weston

Wake Research Associates, Weston

37205

Nashville Medical Research Institute, Nashville

37421

Diseases of the Digestive System, Chattanooga

45219

Consultants for Clinical Research, Cincinnati

53207

Wisconsin Center for Advanced Research, Milwaukee

55905

Mayo Clinic and Mayo Foundation, Rochester

59101

Deaconess Billings Clinic Research Division, Billings

60005

Northwest Gastroenterologists, S.C., Arlington Heights

60637

University of Chicago, Chicago

64131

Gastroenterology and Hepatology, Kansas City

65265

Glenn Gordon, MD, Mexico

68503

Gastroenterology Specialties, P.C., Lincoln

70001

Drug Research Services, Inc., Metairie

70115

LSU School of Medicine, New Orleans

73104

Oklahoma Foundation for Digestive Disease, Oklahoma City

74104

Research Solutions, Tulsa

90806

Long Beach Gastroenterology Assoc., Long Beach

92123

Sharp Rees-Stealy Medical Group, San Diego

94705

Gastroenterology Associates of the East Bay, Berkeley

98004

Northwest Gastroenterology, Bellevue

98405

Tacoma Digestive Disease Center, Tacoma

99204

Inland Empire Gastroenterology, Spokane

06606

Gastroenterology Assoc. of Fairfield Co., Bridgeport

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

01610

Clinical Pharmacology Study Group, Worchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00055497 - Remission in Subjects With Crohn's Disease, 1 Year Phase | Biotech Hunter | Biotech Hunter